Press Release : Novartis Phase III Beovu(R) data -2-

events or otherwise. 
 
   About Novartis 
 
   Novartis is reimagining medicine to improve and extend people's lives. 
As a leading global medicines company, we use innovative science and 
digital technologies to create transformative treatments in areas of 
great medical need. In our quest to find new medicines, we consistently 
rank among the world's top companies investing in research and 
development. Novartis products reach nearly 800 million people globally 
and we are finding innovative ways to expand access to our latest 
treatments. About 110,000 people of more than 140 nationalities work at 
Novartis around the world. Find out more at https://www.novartis.com. 
 
   Novartis is on Twitter. Sign up to follow @Novartis at 
https://twitter.com/novartisnews https://twitter.com/novartisnews 
 
   For Novartis multimedia content, please visit 
https://www.novartis.com/news/media-library 
 
   For questions about the site or required registration, please contact 
[e-mail] 
 
   References 
 
 
   1. Brown D, Wolf S, Garweg JG, et al. Brolucizumab for the treatment of 
      visual impairment due to diabetic macular edema: 52-week results from the 
      KESTREL & KITE studies. Presented at: The Association for Research in 
      Vision and Ophthalmology (ARVO) 2021 Annual Meeting. May 2021. 
 
   2. Eylea [prescribing information] Tarrytown, NY: Regeneron Pharmaceuticals, 
      Inc; 2018. 
 
   3. Beovu [US prescribing information] East Hanover, NJ. Novartis: 2020. 
 
   4. Data on file. KESTREL and KITE Clinical Study Report. Novartis, 2021. 
 
   5. Romero-Aroca P. Managing diabetic macular edema: The leading cause of 
      diabetes blindness. World J Diabetes. 2011;2(6):98-104. 
 
   6. National Eye Institute. Macular Edema. Available at: 
      https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/macular-edema. 
      Accessed April 2021. 
 
   7. National Eye Institute. Diabetic Retinopathy. Available at: 
      https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/diabetic-retinopathy. 
      Accessed April 2021. 
 
   8. Beovu [summary of product characteristics] Basel, Switzerland. Novartis: 
      2020. 
 
   9. Pharma Japan. National Health Insurance Pricing. Available at: 
      https://pj.jiho.jp/sites/default/files/pj/document/2020/05/New%20Drugs%20to%20Be%20Added%20to%20NHI%20Price%20List%20on%20May%2020_1.pdf. 
      Accessed April 2021. 
 
  10. Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug 
      Expert Committee Recommendation. Available at: 
      https://cadth.ca/sites/default/files/cdr/complete/SR0632%20Beovu%20-%20CDEC%20Final%20Recommendation%20%E2%80%93%20May%2025%2C%202020_for%20posting.pdf. 
      Accessed April 2021. 
 
  11. Beovu [prescription medicine decision summary] Australia. Novartis: 2020. 
 
 
   # # # 
 
   Novartis Media Relations 
 
   E-mail: [e-mail] 
 
 
 
 
Peter Zuest                            Amy Wolf 
 Novartis External Communications       Novartis Division Communications 
 + 41 79 899 9812 (mobile)              + 41 79 576 07 23 (mobile) 
 [e-mail]               [e-mail] 
 Julie Masow 
 Novartis Head US External Engagement 
 [phone] 
 [e-mail] 
 
   Novartis Investor Relations 
 
   Central investor relations line: [phone] 
 
   E-mail: [e-mail] 
 
 
 
 
Central                                  North America 
Samir Shah              [phone]  Sloan Simpson  [phone] 
Thomas Hungerbuehler   [phone] 
 Isabella Zinck         [phone] 
 
 
 
 
 
 

(END) Dow Jones Newswires

May 01, 2021 07:05 ET (11:05 GMT)